Ipilimumab-nivolumab as first-line treatment in metastatic NSCLC

被引：1
|
作者：
El-Ghazzi, Nathan [1 ]
Lavaud, Pernelle [2 ]
机构：
[1] Univ Clermont Auvergne, Med Oncol Serv, Ctr Jean Perrin, Clermont Ferrand, France
[2] Univ Paris Saclay, Dept Med Oncol, Gustave Roussy Canc Campus, Villejuif, France
来源：
BULLETIN DU CANCER | 2021年 / 108卷 / 03期
关键词：
Non-small-cell lung carcinoma; Immunotherapy; Checkpoint immune inhibitors; Chemotherapy; PLATINUM-DOUBLET CHEMOTHERAPY; PLUS IPILIMUMAB;
D O I：
10.1016/j.bulcan.2021.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：231 / 233
页数：4
相关论文
共 50 条
  • [21] Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817
    Barlesi, F.
    Audigier-Valette, C.
    Felip, E.
    Ciuleanu, T-E.
    Jao, K.
    Rijavec, E.
    Urban, L.
    Aucoin, J-S.
    Zannori, C.
    Vermaelen, K.
    Aren Frontera, O.
    Ready, N.
    Curioni, A.
    Linardou, H.
    Poddubskaya, E.
    Fischer, J. R.
    Pillai, R.
    Li, S.
    Acevedo, A.
    Paz-Ares, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 33 - +
  • [22] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Brahmer, J. R.
    Ciuleanu, T-E.
    Schenker, M.
    Audigier-Valette, C.
    Zurawski, B.
    Linardou, H.
    Kim, S-W.
    Otterson, G. A.
    Salman, P.
    De La Mora Jimenez, E.
    Lesniewski-Kmak, K.
    Ahmed, S.
    Albert, I.
    Barlesi, F.
    Feeney, K.
    Frickhofen, N.
    Li, A.
    Sun, P.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
  • [23] Ipilimumab and Nivolumab as First-Line Treatment of Patients with Renal Cell Carcinoma: The Evidence to Date
    Sheng, Iris Y.
    Ornstein, Moshe C.
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4871 - 4881
  • [24] Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan
    Paly, Victoria Federico
    Hikichi, Yusuke
    Baker, Timothy
    Itakura, Eijun
    Chandran, Nisha
    Harrison, James
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (12) : 1542 - 1552
  • [25] Bempegaldesleukin/Nivolumab and Challenges in First-line Treatment of Metastatic Urothelial Carcinoma
    Miron, Benjamin
    Geynisman, Daniel M.
    EUROPEAN UROLOGY, 2022, 82 (04) : 374 - 376
  • [26] Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
    Stoff, Ronen
    Grynberg, Shirly
    Asher, Nethanel
    Laks, Shachar
    Steinberg, Yael
    Schachter, Jacob
    Shapira-Frommer, Ronnie
    Ben-Betzalel, Guy
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] An Indirect Comparison of Pembrolizumab Monotherapy Versus Ipilimumab plus Nivolumab for First-Line Metastatic NSCLC with PD-L1 TPS≥1%
    Halmos, B.
    Burke, T.
    Kalyvas, C.
    Insinga, R.
    Vandormael, K.
    Frederickson, A.
    Piperdi, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S23 - S24
  • [28] First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?
    Burtness, Barbara
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2134 - +
  • [29] Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses.
    Doshi, Sahil D.
    Lopez Sanmiguel, Andrea
    Knezevic, Andrea
    Kotecha, Ritesh R.
    Shah, Neil J.
    Carlo, Marie
    Feldman, Darren R.
    Motzer, Robert J.
    Voss, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 540 - 540
  • [30] Indirect comparison of pembrolizumab monotherapy versus nivolumab plus ipilimumab in first-line metastatic lung cancer
    Halmos, Balazs
    Burke, Thomas
    Kalyvas, Chrysostomos
    Insinga, Ralph
    Vandormael, Kristel
    Frederickson, Andrew
    Piperdi, Bilal
    IMMUNOTHERAPY, 2022, 14 (05) : 295 - 307
12345